Literature DB >> 4779981

Ethambutol and rifampicin serum levels in children: second report on the combined administration of ethambutol and rifampicin.

H Hussels, U Kroening, K Magdorf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4779981     DOI： 10.1007/bf02179950

Source DB:  PubMed          Journal:  Pneumonologie        ISSN： 0033-4073


× No keyword cloud information.
  5 in total

1.  [Comparison of blood concentration of rifampicin between administration before and after breakfast].

Authors:  M Tsukamura; J Yokouchi; T Miwa; K Koike
Journal:  Kekkaku       Date:  1972-04

2.  Studies on the antituberculous activity of ethambutol in monkeys.

Authors:  L H Schmidt
Journal:  Ann N Y Acad Sci       Date:  1966-04-20       Impact factor: 5.691

3.  [Serum ethambutol concentration in childhood].

Authors:  H Hussels; H S Otto
Journal:  Pneumonologie       Date:  1971

4.  [Procedure for concentration determination of the new antibiotic rifampicin in serum].

Authors:  H J Hussels
Journal:  Med Lab (Stuttg)       Date:  1969-09

5.  [Rifampicin inhibitory titer in wild strains of Mycobacterium and Rifampicin serum concentrations in tuberculous patients].

Authors:  H Hussels; I Schütz
Journal:  Beitr Klin Erforsch Tuberk Lungenkr       Date:  1969
  5 in total
  10 in total

1.  Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Authors:  Hongmei Yang; Anthony Enimil; Fizza S Gillani; Sampson Antwi; Albert Dompreh; Antoinette Ortsin; Eugene Adu Awhireng; Maxwell Owusu; Lubbe Wiesner; Charles A Peloquin; Awewura Kwara
Journal:  Pediatr Infect Dis J       Date:  2018-01       Impact factor: 2.129

2.  Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.

Authors:  S M Graham; D J Bell; S Nyirongo; R Hartkoorn; S A Ward; E M Molyneux
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 3.  Pharmacokinetics of First-Line Anti-Tubercular Drugs.

Authors:  Aparna Mukherjee; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2019-03-26       Impact factor: 1.967

4.  Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Authors:  S Thee; J A Seddon; P R Donald; H I Seifart; C J Werely; A C Hesseling; B Rosenkranz; S Roll; K Magdorf; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

Review 5.  Pharmacokinetics of anti-tuberculosis drugs in children.

Authors:  Geetha Ramachandran; A K Hemanth Kumar; Soumya Swaminathan
Journal:  Indian J Pediatr       Date:  2010-12-17       Impact factor: 1.967

6.  Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations.

Authors:  Yasuhiro Horita; Abdullah Alsultan; Awewura Kwara; Sampson Antwi; Antony Enimil; Antoinette Ortsin; Albert Dompreh; Hongmei Yang; Lubbe Wiesner; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

7.  Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing.

Authors:  Wyatt J Roth; Candice B Kissinger; Robyn R McCain; Bruce R Cooper; Jeremy N Marchant-Forde; Rachel C Vreeman; Sophia Hannou; Gregory T Knipp
Journal:  AAPS J       Date:  2013-04-18       Impact factor: 4.009

8.  Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.

Authors:  Awewura Kwara; Anthony Enimil; Fizza S Gillani; Hongmei Yang; Anima M Sarfo; Albert Dompreh; Antoinette Ortsin; Lawrence Osei-Tutu; Sandra Kwarteng Owusu; Lubbe Wiesner; Jennifer Norman; Jaclynn Kurpewski; Charles A Peloquin; Daniel Ansong; Sampson Antwi
Journal:  J Pediatric Infect Dis Soc       Date:  2015-05-26       Impact factor: 3.164

9.  Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.

Authors:  A Bekker; H S Schaaf; H R Draper; L van der Laan; S Murray; L Wiesner; P R Donald; H M McIlleron; A C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

10.  Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.

Authors:  Hendrik Simon Schaaf; Marianne Willemse; Karien Cilliers; Demetre Labadarios; Johannes Stephanus Maritz; Gregory D Hussey; Helen McIlleron; Peter Smith; Peter Roderick Donald
Journal:  BMC Med       Date:  2009-04-22       Impact factor: 8.775
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.